BioHarvest says its platform can produce target sweetener in Tate & Lyle program

Impact · against what's priced in

BioHarvest (BHST) sees a modest positive catalyst as technical validation of its sweetener production increases the probability of future commercial licensing. Royal Road Minerals (RYR) receives a positive update following the identification of silver-antimony veins in Colombia.

RYR+0.60: No priced-in read yet
In context: The company has identified significant silver-antimony veins at the Margaritas target in Colombia, expanding the known resource potential of the exploration project.
Read from the article alone

BioHarvest says its platform can produce target sweetener in Tate & Lyle program

biotech
BHST
RYR
botanical synthesis
food tech
ingredient innovation
pharma
sweeteners

Search tags

BioHarvest says its platform can produce target sweetener in Tate & Lyle program

What matters in this story

U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

BioHarvest says its platform can produce target sweetener in Tate & Lyle program

What matters in this story

U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

How each ticker is affected

Connected tickers

Track these names every morning.

Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?

Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?

BioHarvest says its platform can produce target sweetener in Tate & Lyle program

What matters in this story

Next reads from the same story arc

U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

BioHarvest says its platform can produce target sweetener in Tate & Lyle program

What matters in this story

Next reads from the same story arc

U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

How each ticker is affected

Connected tickers

Track these names every morning.

Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?

Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?